Herpes Zoster
Conditions
Interventions
Control group:HV-PRF (with voltage of 100V, frequency of 2Hz, pulse width of 20ms, single cycle duration of 300 seconds).
Experimental group:The HV-PRF (with voltage of 100V, frequency of 2Hz, pulse width of 20ms, and single stimulation lasting for 300 seconds) combined stimulation mode treatment (adjusted to the sensory
Sponsors
Xiamen Medical University Affiliated Second Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. The diagnosis is in accordance with the diagnostic criteria of the "Chinese Expert Consensus on the Whole-process Management of Herpes Zoster-related Pain". 2. Typical herpes zoster rash history, and the pain is distributed along a single-sided nerve segment. 3. Age range: 18-85 years old. Gender: No restrictions. 4. Signed informed consent form, and able to cooperate with follow-up and assessment. 5. Imaging support (not necessary but recommended): MRI/CT shows no structural lesions such as tumors or nerve root compression in the responsible nerve segments.
Exclusion criteria
Exclusion criteria: 1. Systemic disease interference: Severe coagulation dysfunction (INR > 1.5, platelet count 9%) or severe cardiovascular diseases (NYHA cardiac function III-IV grade). 2. Nervous system diseases: Complicated with other neuropathies (such as diabetic neuropathy, spinal cord injury, multiple sclerosis). Central pain syndrome or complex regional pain syndrome (CRPS). 3. Psychiatric and psychological factors: Severe mental disorders (severe depression, schizophrenia) or cognitive impairment (MMSE < 24 points). History of drug abuse (dependence on opioids, benzodiazepines). 4. Treatment-related contraindications: Pregnant or lactating women. Allergic to radiofrequency treatment or local anesthetics (lidocaine). Recently (within 3 months) received spinal cord electrical stimulation, nerve ablation surgery or other interventional treatments. 5. Other exclusion factors: Expected survival period < 6 months (such as patients with advanced tumors). Participation in other clinical trials may interfere with the results of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Numerical rating scale, NRS;Visual analogue scale was used, VAS;Fecal microbiota detection; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hamilton Depression Scale;Hamilton Anxiety Scale;Pittsburgh Sleep Scale, PSQI;Cd4-positive cells/helper T cells 2, TH1/TH2;C-reactive protein, CRP; | — |
Countries
China
Contacts
Public ContactZhang Guanghui
The Second Affiliated Hospital of Xiamen Medical University
Outcome results
None listed